Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LORL
2101
DELISTED
Loral Space and Communications, Inc.
LORL
| $3.16M | ﹤0.01% |
97,700
+19,000
| +24% | +$697K |
|
|
PRFT
2102
DELISTED
Perficient Inc
PRFT
| $3.15M | ﹤0.01% |
+68,393
| New | +$2.79M |
|
2103
Agree Realty
ADC
$9.3B
| $3.14M | ﹤0.01% |
+44,800
| New | +$3.3M |
|
2104
Espey Mfg & Electronics Corp
ESP
$192M
| $3.13M | ﹤0.01% |
145,087
-1,900
| -1% | -$41.9K |
|
2105
Mustang Bio
MBIO
$4.5M
| $3.13M | ﹤0.01% |
1,023
+86
| +9% | +$197K |
|
|
CTIC
2106
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $3.11M | ﹤0.01% |
1,967,914
+90,025
| +5% | +$85.3K |
|
2107
Banner Corp
BANR
$2.52B
| $3.11M | ﹤0.01% |
54,900
+20,801
| +61% | +$1.15M |
|
2108
WisdomTree Europe Hedged Equity Fund
HEDJ
$1.88B
| $3.11M | ﹤0.01% |
88,000
+54,600
| +163% | +$1.88M |
|
|
RDFN
2109
DELISTED
Redfin
RDFN
| $3.09M | ﹤0.01% |
+146,200
| New | +$2.8M |
|
2110
Ecovyst
ECVT
$1.14B
| $3.08M | ﹤0.01% |
179,400
+21,200
| +13% | +$340K |
|
2111
Superior Group of Companies
SGC
$208M
| $3.08M | ﹤0.01% |
227,600
+4,300
| +2% | +$62.1K |
|
2112
Karyopharm Therapeutics
KPTI
$45.8M
| $3.08M | ﹤0.01% |
+10,700
| New | +$2.32M |
|
|
FCCY
2113
DELISTED
1st Constitution Bancorp
FCCY
| $3.08M | ﹤0.01% |
138,953
+13,153
| +10% | +$263K |
|
|
VNTR
2114
DELISTED
Venator Materials PLC
VNTR
| $3.07M | ﹤0.01% |
800,853
+172,715
| +27% | +$562K |
|
|
WWE
2115
DELISTED
World Wrestling Entertainment
WWE
| $3.06M | ﹤0.01% |
47,214
-1,573,700
| -97% | -$99.5M |
|
2116
Texas Roadhouse
TXRH
$13.6B
| $3.06M | ﹤0.01% |
54,372
-324,500
| -86% | -$17.8M |
|
|
CSLT
2117
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $3.06M | ﹤0.01% |
2,299,550
+469,950
| +26% | +$656K |
|
|
CDTX
2118
DELISTED
Cidara Therapeutics
CDTX
| $3.06M | ﹤0.01% |
39,783
+5,999
| +18% | +$275K |
|
|
TCO
2119
DELISTED
Taubman Centers Inc.
TCO
| $3.05M | ﹤0.01% |
+98,100
| New | +$3.36M |
|
|
SCX
2120
DELISTED
The L.S. Starrett Company
SCX
| $3.04M | ﹤0.01% |
532,076
+42,855
| +9% | +$243K |
|
2121
Friedman Industries
FRD
$331M
| $3.04M | ﹤0.01% |
504,120
+10,100
| +2% | +$64.6K |
|
2122
TETRA Technologies
TTI
$1.27B
| $3.03M | ﹤0.01% |
1,547,606
+405,890
| +36% | +$653K |
|
|
LBC
2123
DELISTED
Luther Burbank Corporation Common Stock
LBC
| $3.03M | ﹤0.01% |
262,868
+66,002
| +34% | +$751K |
|
2124
British American Tobacco
BTI
$123B
| $3.02M | ﹤0.01% |
71,234
-218,000
| -75% | -$8.22M |
|
2125
Veru
VERU
$46.5M
| $3.02M | ﹤0.01% |
90,291
+50,760
| +128% | +$1.13M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.